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Abstract
Coagulase-positive staphylococci, which frequently colonize the mucosal surfaces of ani-
mals, also cause a spectrum of opportunistic infections including skin and soft tissue infec-
tions, urinary tract infections, pneumonia, and bacteremia. However, recent advances in
bacterial identification have revealed that these common veterinary pathogens are in fact
zoonoses that cause serious infections in human patients. The global spread of multidrug-
resistant zoonotic staphylococci, in particular the emergence of methicillin-resistant organ-
isms, is now a serious threat to both animal and human welfare. Accordingly, new therapeu-
tic targets that can be exploited to combat staphylococcal infections are urgently needed.
Enzymes of the methylerythritol phosphate pathway (MEP) of isoprenoid biosynthesis rep-
resent potential targets for treating zoonotic staphylococci. Here we demonstrate that fosmi-
domycin (FSM) inhibits the first step of the isoprenoid biosynthetic pathway catalyzed by
deoxyxylulose phosphate reductoisomerase (DXR) in staphylococci. In addition, we have
both enzymatically and structurally determined the mechanism by which FSM elicits its
effect. Using a forward genetic screen, the glycerol-3-phosphate transporter GlpT that facili-
tates FSM uptake was identified in two zoonotic staphylococci, Staphylococcus schleiferi
and Staphylococcus pseudintermedius. A series of lipophilic ester prodrugs (termed
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MEPicides) structurally related to FSM were synthesized, and data indicate that the pres-
ence of the prodrug moiety not only substantially increased potency of the inhibitors against
staphylococci but also bypassed the need for GlpT-mediated cellular transport. Collectively,
our data indicate that the prodrug MEPicides selectively and robustly inhibit DXR in zoonotic
staphylococci, and further, that DXR represents a promising, druggable target for future
development.
Author summary
The proliferation of microbial pathogens resistant to the current pool of antibiotics is a
major threat to public health. Drug resistance is pervasive in staphylococci, including sev-
eral species that can cause serious zoonotic infections in humans. Thus, new antimicrobial
agents are urgently needed to combat these life-threatening, resistant infections. Here we
establish the MEP pathway as a promising new target against zoonotic staphylococci. We
determine that fosmidomycin (FSM) selectively targets the isoprenoid biosynthesis path-
way in zoonotic staphylococci and use forward genetics to identify the transporter that
facilitates phosphonate antibiotic uptake. Employing this knowledge, we synthesized a
series of potent antibacterial prodrugs that circumvent the transporter. Together, these
novel prodrug inhibitors represent promising leads for further drug development against
zoonotic staphylococci.
Introduction
Coagulase-positive staphylococci, such as S. pseudintermedius and S. schleiferi subsp. coagu-
lans, are leading causes of skin, soft tissue, and invasive infections in companion animals such
as dogs and cats. In addition, these organisms cause zoonotic infections in humans that are
clinically indistinguishable from infections with S. aureus including pneumonia, skin and soft
tissue infections, hardware infections, and bacteremia[1–5]. Newer clinical microbiological
techniques, such as mass spectrometry, now readily distinguish S. aureus from zoonotic coagu-
lase-positive staphylococci, which were previously often misidentified[3,6,7]. Thus, there is a
growing recognition of the importance of zoonotic staphylococci in human disease. Because
mecA-mediated methicillin resistance is on the rise in both veterinary and human clinical iso-
lates, new antibacterial strategies to specifically target zoonotic staphylococci are highly desir-
able[8–10].
Two distinct and independent pathways for isoprenoid biosynthesis have evolved, the
mevalonate pathway and a mevalonate-independent route that proceeds through methylery-
thritol phosphate, called the MEP pathway[11]. Unusual among bacteria, the least common
ancestor of all Staphylococcus spp. appears to have possessed both pathways. Primate-associ-
ated staphylococcal lineages, including S. aureus, possess the mevalonate pathway, and evi-
dence suggests that mevalonate pathway activity is required for peptidoglycan synthesis,
growth, and virulence[12–14]. In contrast, nonprimate-associated staphylococcal species,
including S. pseudintermedius and S. schleiferi, utilize the MEP pathway for isoprenoid biosyn-
thesis[15]. Importantly, humans and other mammals lack homologs of MEP pathway
enzymes, and MEP pathway activity is required for cellular growth in all organisms in which it
has been experimentally determined[16–21]. Thus, new chemical inhibitors of MEP pathway
enzymes hold promise as effective antimicrobials that may provide a high margin of safety.
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The first dedicated enzyme of the MEP pathway, deoxyxylulose phosphate reductoisome-
rase (DXR; E.C. 1.1.1.267), is rate-limiting for MEP pathway activity. DXR is known to be sus-
ceptible to small molecule inhibition. For example, the phosphonic acid antibiotic
fosmidomycin (FSM) is a slow, tight-binding, competitive inhibitor of DXR[22]. FSM is safe
and well-tolerated in humans and animals[23–25]. Unfortunately, FSM has poor oral bioavail-
ability and a short serum half-life, which has hampered clinical efficacy. Moreover, the charged
nature of FSM and its phosphonate analogs has challenged their clinical development as the
compounds are excluded from cells unless actively transported. As a result, many microorgan-
isms, such as Mycobacterium tuberculosis and Toxoplasma gondii, are inherently resistant to
FSM (due to poor cellular uptake) even though FSM potently inhibits their DXR orthologs in
vitro[16,18,26]. In Gram-negative organisms, FSM resistance can be achieved by reduced
expression or activity of a glycerol-3-phosphate/Pi antiporter (GlpT) [27,28], presumed to be
required for FSM import.
In this work, we use the highly specific inhibitor FSM to chemically validate the MEP path-
way enzyme DXR as an essential, druggable antibacterial target for zoonotic staphylococcal
infections. Furthermore, we establish the structural and enzymatic mechanism of staphylococ-
cal DXR inhibition by FSM. Using a chemical genomics approach, we define the genetic basis
of FSM resistance in zoonotic staphylococci and define the FSM transporter GlpT in these
strains. Finally, we reveal that structurally related lipophilic ester prodrugs (called MEPicides)
yield substantially increased potency and circumvent the need for GlpT-dependent import.
Thus, lipophilic prodrugs provide a promising new approach to combat zoonotic staphylococ-
cal infections.
Results
Anti-staphylococcal activity of canonical MEP pathway inhibitors
Because previous evidence had suggested that zoonotic staphylococci might be sensitive to
MEP pathway inhibition, we quantified the dose-dependent antibacterial effects of FSM and
FR-900098, a structurally similar DXR inhibitor (Fig 1)[15]. FSM was 5-10-fold more potent
against both S. schleiferi (IC50 = 0.78 ± 0.13 μM) and S. pseudintermedius (IC50 =
0.31 ± 0.04 μM), respectively (Table 1), despite modest chemical differences between the two
inhibitors. Data indicate that both compounds elicit their effect via a bacteriostatic mecha-
nism-of-action, as neither caused a substantial drop in viable cells (S1 Fig). Because S. aureus
does not utilize the MEP pathway for isoprenoid biosynthesis, neither FSM nor FR-900098
inhibit S. aureus growth (Table 1). Together, these data indicate that both S. schleiferi and S.
pseudintermedius have a functional MEP pathway that is required for bacterial growth.
Fosmidomycin inhibits isoprenoid metabolism in zoonotic staphylococci
To establish the presence of MEP pathway intermediates and to determine the cellular mecha-
nism-of-action of FSM, we performed targeted metabolic profiling of MEP pathway interme-
diates in S. schleiferi and S. pseudintermedius, with and without drug treatment. We confirmed
that both species contain MEP pathway intermediates, including the DXR substrate, deoxyxy-
lulose 5-phosphate (DOXP) and the downstream metabolites 4-diphosphocytidyl-2-C-methy-
lerythritol (CDP-ME) and methylerythritol cyclodiphosphate (MEcPP) (Fig 2). Upon FSM
treatment, intracellular levels of DOXP increase dramatically (23.8-fold; p < 0.05 and
34.8-fold; p< 0.05 for S. schleiferi and S. pseudintermedius, respectively), consistent with DXR
inhibition. Similarly, intracellular levels of CDP-ME and MEcPP are substantially reduced fol-
lowing FSM treatment (CDP-ME 5.5-fold; p< 0.05 and 2.6-fold; p< 0.05 and MEcPP 4.5-fold;
p< 0.01 and 2.4-fold; p< 0.05 for S. schleiferi and S. pseudintermedius, respectively),
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consistent with FSM-mediated reduction in MEP pathway metabolism. Together, these data
confirm the presence of active MEP pathway metabolism in zoonotic staphylococci and estab-
lish that FSM inhibits growth through MEP pathway inhibition.
Fosmidomycin is a competitive inhibitor of S. schleiferi DXR
To establish the enzymatic mechanism-of-action of DXR inhibitors against staphylococci, we
cloned and purified S. schleiferi DXR (S2 Fig; S1 Table). Enzymatic characterization of DXR
confirmed a Michaelis constant (Km) [DOXP] (0.52 ± 0.08 mM), similar to that of other DXR
orthologs (Fig 3A)[29,30]. Both FSM and FR-900098 inhibit S. schleiferi DXR in a dose-depen-
dent manner (Table 1). Further, we confirm that DXR inhibition by FSM is competitive with
respect to the DOXP substrate, with a Ki [DOXP] of 0.29 ± 0.022 μM (Fig 3B).
Fig 1. Structures of Dxr inhibitors tested against Staphylococcus spp. Displayed are the structures of the Dxr
inhibitors used in this study. POM = (CH3)3CCOOCH2.
https://doi.org/10.1371/journal.ppat.1007806.g001
Table 1. Inhibitory effect of MEPicides against the S. schleiferi DXR enzyme and in vitro activity against Staphylococcus spp.
Compound S. schleiferi DXR enzyme S. schleiferi S. pseudintermedius S. aureus
IC50 [μM] IC50 [μM] IC50 [μM] IC50 [μM]
FSM 0.67 ± 0.06 0.78 ± 0.13 0.31 ± 0.04 > 100
FR-900098 1.00 ± 0.18 41.06 ± 6.65 34.14 ± 6.54 > 100
Compound 1 3.31 ± 1.02 55.50 ± 2.41 54.45 ± 1.14 > 100
Compound 2 > 100 0.10 ± 0.01 0.26 ± 0.03 > 100
Compound 3 0.41 ± 0.11 4.17 ± 0.47 4.31 ± 0.51 > 100
Compound 4 12.56 ± 1.98 0.03 ± 0.00 0.21 ± 0.04 > 90
Data represent the mean ± SEM from at least three independent experiments.
https://doi.org/10.1371/journal.ppat.1007806.t001
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Structural basis of fosmidomycin inhibition
To establish the structural basis of FSM action, we solved the three-dimensional structures of
S. schleiferi DXR as an apoenzyme and a FSM complex to 2.15 Å and 2.89 Å resolution, respec-
tively (S2 Table; Fig 4). S. schleiferi DXR is a physiologic dimer with each monomer related by
crystallographic symmetry (Fig 4A). A DALI search identified multiple DXR from Escherichia
coli, Plasmodium falciparum, M. tuberculosis, and other microbes (Z-scores: 49–51; r.m.s.d.
~1.6 Å2 for 370–400 Cα-atoms; 39–40% amino acid sequence identity)[31–36]. The monomer
consists of three regions (Fig 4A): an N-terminal α/β-domain with a central 7-stranded β-sheet
(β1-β7) and 7 α-helices that serves as the nucleotide binding site; a middle region of the pro-
tein that includes a second β-sheet (β8-β11) and 4 α-helices (α8 and α12-α14); and a C-termi-
nal α-helical domain (α9-α11 and α15-α18) that locks FSM into the active site[37].
Clear electron density for FSM was observed in the active site (Fig 4B) and revealed multi-
ple protein-ligand interactions (Fig 4C). Interactions with Ser170, Ser206, Asn211, and Lys212
positions the FSM phosphonate toward the catalytic histidine (His241) and the NADP(H)
binding site. The hydroxamic acid of the ligand contacts Asp144, Glu146, and Glu215. Addi-
tional van der Waals contacts are provided by Trp196, which resides in the α10-α11 loop.
Comparison of the S. schleiferi DXR apoenzyme and FSM complex structures reveals how the
C-terminal capping region (α9-α11 and α16–18) shifts position to allow for the α10-α11 loop
to position Trp196 adjacent to the inhibitor (Fig 4D). Movement of this flexible loop is a key
feature for FSM inhibition of DXR from a variety of microorganisms[38]. The residues that
interact with FSM in the S. schleiferi DXR are conserved in the crystal structures of DXR from
Fig 2. FSM inhibits the MEP pathway in Staphylococcus spp. MEP pathway metabolites were compared between untreated (UNT) S.
schleiferi (A) and S. pseudintermedius (B) and bacteria treated with FSM at 10x the respective IC50 values. After 2 h treatment, bacterial
cells were harvested and the cell pellets analyzed by LC-MS/MS. Displayed are the means ± SD of the metabolite levels (in attograms
(ag)/cell) from three independent experiments. P-values were determined using a Student’s t-test.
https://doi.org/10.1371/journal.ppat.1007806.g002
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E. coli, P. falciparum, and M. tuberculosis, with some variation in the sequence of the α10-α11
loop, although the tryptophan that contacts FSM is conserved in all these enzymes [34,36,37].
Resistance selection reveals a candidate FSM transporter, GlpT
To establish the molecular basis of compound uptake, we performed independent, parallel,
forward genetic screens for FSM resistance in both S. schleiferi and S. pseudintermedius (Fig
5A). Candidate FSM resistant (FSMR) strains were colony purified and resistance was
Fig 3. Inhibition of staphylococcal DXR by FSM is competitive with DOXP. (A) S. schleiferi DXR velocity in μmol
NADPH/min with respect to the DOXP concentration in mM. Displayed are the means ± SD from three independent
experiments. (B) Lineweaver−Burk double reciprocal plots of S. schleiferi DXR activity over a range of DOXP substrate
concentrations, for illustrative purposes only.
https://doi.org/10.1371/journal.ppat.1007806.g003
PLOS PATHOGENS MEPicides for zoonotic staph
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1007806 June 4, 2020 6 / 22
quantified by MIC determination (Fig 5B and S3 Table). For both S. schleiferi and S. pseudin-
termedius, FSMR strains possessed FSM MICs >100-fold higher than the wild-type parental
lines. We employed whole genome sequencing to characterize the single-nucleotide polymor-
phisms (SNPs) that were present in the resistant strains (S4 Table). In both species, FSM selec-
tive pressure enriched for new nonsynonymous changes in a single homologous locus,
RN70_03745 (10/11 S. schleiferi strains) and SPSE_0697 (10/12 S. pseudintermedius strains)
(S3A and S3B Fig). These loci are close homologs (>90% sequence identity and 95.4%
sequence similarity), which belong to the glycerol-3-phosphate transporter (GlpT) subfamily
(Interpro: IPR005267) of the major facilitator superfamily (MFS) family of proteins (Interpro:
IPR011701). These data suggest a model in which GlpT mediates FSM import, such that loss
of GlpT function confers FSM resistance.
Fig 4. Crystal structure of S. schleiferi DXR. (A) Overall structure of the S. schleiferi DXR•FSM complex. The dimer is shown as a ribbon diagram with α-
helices and β-strands of one monomer colored gold and blue, respectively. The position of FSM (space-filling model) in one monomer is indicated. (B)
Electron density for FSM is shown as a 2Fo-Fc omit map (1 σ). (C) Stereoview of FSM binding in the active site. Dotted lines indicate protein-ligand
interactions. (D) Comparison of S. schleiferi DXR apoenzyme and FSM complex structures. Structural changes in the active site region between the apoenzyme
(rose) and FSM complex (gold) are shown. The major change in the position of the α10-α11 loop is emphasized by the position of Trp196 in each structure.
https://doi.org/10.1371/journal.ppat.1007806.g004
PLOS PATHOGENS MEPicides for zoonotic staph
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Fig 5. Successful selection for FSM resistance. (A) Wild-type and FSM-resistant isolates from S. schleiferi (top) or S. pseudintermedius (bottom) were struck on LB agar
plates with (right) and without (left) 32 μM FSM. (B) Distribution of the MIC values for WT (gray) and FSM-resistant mutants (black) from S. schleiferi (circles) and S.
pseudintermedius (triangles). Displayed are the mean values for each strain from three independent experiments.
https://doi.org/10.1371/journal.ppat.1007806.g005
Fig 6. GlpT is required for FSM import. Wild-type (WT) and FSM-resistant, glpT mutant S. schleiferi isolates (strains
3408, 4494, 7376, and 8400) were treated with FSM and the intracellular concentrations of the drug were measured by
LC-MS. Displayed are the mean values ± SEM (in attograms (ag)/cell) from three independent experiments.
https://doi.org/10.1371/journal.ppat.1007806.g006
PLOS PATHOGENS MEPicides for zoonotic staph
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Fosmidomycin-resistance alleles of the candidate transporter, GlpT
We predicted that the FSM-resistance alleles likely reduce GlpT function. In S. schleiferi, nine
distinct alleles were found with GlpT changes: two with nonsense mutations and seven others
with amino acid variants that are predicted to be highly deleterious (Polyphen-2 score>0.9; S3
Table)[39]. Similarly, in S. pseudintermedius, a total of seven distinct alleles were identified
with GlpT sequence changes. Of these, one contained a nonsense mutation and six other GlpT
variants contained amino acid substitutions that are strongly predicted to reduce function
(Polyphen-2 score >0.9; S3 Table). FSM-resistant variants map along the length of the nearly
50 Kd GlpT transporter, in both S. schleiferi and S. pseudintermedius (S3A and S3B Fig). Alto-
gether, the finding of multiple independent loss-of-function alleles, including nonsense muta-
tions, in two different selections in distinct organisms, strongly suggests that reduced GlpT
function is responsible for FSM resistance in these strains.
Fosmidomycin-resistant glpT strains fail to import fosmidomycin
To experimentally address whether GlpT mediates FSM import, we developed a novel liquid-
chromatography-mass spectrometry (LC-MS/MS) method to quantify intracellular concentra-
tions of FSM in bacteria. Using this method, we evaluated the intracellular concentration of
FSM in drug-treated wild-type S. schleiferi compared to FSM-resistant glpT strains. While
wild-type S. schleiferi readily accumulates FSM, four independent FSM-resistant S. schleiferi
with glpT mutations do not, establishing staphylococcal GlpT as the first experimentally vali-
dated phosphonic acid antibiotic transporter (Fig 6). For one of these strains (4494), the nucle-
otide polymorphism in the GlpT locus is the only genetic change that distinguishes this FSM-
resistant strain from its FSM-sensitive parental line (S4 Table).
Lipophilic ester prodrugs with improved anti-staphylococcal potency
Due to their charged nature, phosphonic acid antibiotics have poor cellular penetration and
bioavailability, and serum half-lives are relatively brief[23,25,40]. In the ongoing effort to
develop new treatments for malaria and tuberculosis by improving upon the drug-like proper-
ties of phosphonates, numerous lipophilic ester prodrugs that target DXR have been generated
[41–53]. Our phosphonate parent compounds (1 and 3) are similar in anti-staphylococcal
potency to FSM and FR-900098 (Fig 1 and Table 1); however, lipophilic modification of either
compound dramatically improves potency (in most cases by 100-fold) against both S. schleiferi
and S. pseudintermedius (compare compound 1 to its prodrug, compound 2, and compound 3
to its prodrug, compound 4) (Fig 1 and Table 1). As expected, prodrugs 2 and 4 poorly inhibit
purified recombinant S. schleiferi DXR in vitro, since cleavage of the prodrug moiety is
required for activity (Table 1). Our data suggest that lipophilic ester modifications improves
uptake of the DXR inhibitors, and that active phosphonates are released intracellularly for tar-
get inhibition.
Lipophilic prodrugs bypass need for GlpT-mediated transport
We anticipated that our lipophilic ester prodrugs do not require active cellular transport. To
evaluate whether GlpT is required for prodrug uptake, we characterized the MEPicide sensitiv-
ity of four different FSMR glpT mutant S. schleiferi strains. As expected, we find that FSMR
glpT strains are cross-resistant to the phosphonate parent drug (compound 3), suggesting a
common mechanism of transport (Fig 7). In contrast, FSMR glpT strains remain sensitive to
the MEPicide prodrugs compounds 2 and 4, supporting a model in which GlpT mediates
PLOS PATHOGENS MEPicides for zoonotic staph
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Fig 7. glpT mutant staphylococci are sensitive to MEPicide prodrugs. Wild-type (WT) and FSM-resistant, glpT mutant S. schleiferi isolates (strains 3408, 4494, 7376,
and 8400) were treated with MEPicides and the MIC values determined during overnight growth. Displayed are the mean values of the fold change (resistant isolate/
WT) ± SEM from at least three independent experiments. �MIC values observed for glpT strain 7376 were identical in three independent experiments performed in
technical duplicate.
https://doi.org/10.1371/journal.ppat.1007806.g007
Fig 8. Model. In wild-type zoonotic staphylococci, GlpT transports the MEP pathway inhibitor FSM intracellularly
where it inhibits its target, DXR. In staphylococci with glpT mutations, FSM is excluded from cells, resulting in FSM
resistance. In contrast, lipophilic prodrug MEPicides do not require active transport and remain effective.
https://doi.org/10.1371/journal.ppat.1007806.g008
PLOS PATHOGENS MEPicides for zoonotic staph
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phosphonate transport, with the ester modifications substantially improving cellular uptake
(Fig 8)[21].
Discussion
S. schleiferi and the Staphylococcus intermedius group (SIG) (including S. pseudintermedius, S.
intermedius, and S. delphini) cause pyodermic infections in companion animals, such as dogs
and cats[8]. Treatment of these infections is complicated by rising rates of antimicrobial resis-
tance, particularly methicillin-resistance[54]. A growing recognition that SIG species also
cause zoonotic human infections, indistinguishable from infections with S. aureus, has led to
new urgency in the search for additional therapeutics against these organisms. The non-meva-
lonate pathway of isoprenoid biosynthesis through MEP has been previously explored for
development of targeted therapeutics for malaria and tuberculosis. In this current work, we
establish the MEP pathway enzyme DXR as an attractive new therapeutic target for treatment
of infections due to zoonotic staphylococci.
The MEP pathway has a number of major advantages as an antimicrobial target for veteri-
narian applications. Since mammals utilize the mevalonate pathway for isoprenoid biosynthe-
sis, they lack homologs of the MEP pathway enzymes. As a result, MEP pathway inhibition is
expected to have a high therapeutic index. Indeed, previous work indicates that the MEPicides
are nontoxic to human cell lines and are well-tolerated in animal models (IC50 of compound 2
against HepG2 cells > 100 μM; IC50s of compounds 3 and 4 against HepG2 cells> 50 μM [42,
53]. Moreover, FSM has been well-tolerated in preclinical and Phase I and II human studies
[23–25,55,56]. As an additional advantage of these agents, use of antibiotics in animal health
and agriculture has been implicated as a major driver of antimicrobial resistance in human
pathogens[57–60]. Of particular relevance to treatment of canine and feline infections, the
close physical contact between owners and household pets facilitates not only the cross-coloni-
zation of organisms but also direct transfer of drug-resistance traits[61–63]. Because human-
associated staphylococci, including S. aureus, S. warnerii, and S. epidermidis, use the mevalo-
nate pathway for isoprenoid biosynthesis, they are not susceptible to MEP pathway inhibitors
(Table 1). Importantly, while Gram-negative organisms such as E. coli and Klebsiella pneumo-
niae are modestly susceptible to MEP pathway inhibition, our lipophilic prodrug compound 2
does not inhibit growth of these organisms (S5 Table). Our MEPicide compounds therefore
have a highly specific and valuable antimicrobial spectrum, which may help break the cycle of
resistance transfer from antibiotic-treated animals to the microbiota of humans.
In the current study, we establish the cellular, enzymatic, and structural mechanisms-of-
action of FSM against zoonotic staphylococci. We confirm that FSM is a competitive inhibitor
of staphylococcal DXR, interrupts cellular isoprenoid biosynthesis, and inhibits growth of zoo-
notic staphylococci. Of note, the staphylococcal DXR enzyme appears somewhat distinct from
previously characterized orthologs, particularly in the α10-α11 loop sequence, which could be
explored with additional SAR studies (Fig 4). Together, our work provides insights into differ-
ences in staphylococcal DXR that may be key to driving future structure-based inhibitor
design efforts.
A well-appreciated liability of antibacterial phosphonates, including fosfomycin and FSM,
has been the ready acquisition of resistance through loss of transport [27,64–66]. Our work
establishes GlpT as the phosphonic acid antibiotic transporter in zoonotic staphylococci (Fig
6). Identification of multiple, independent loss-of-function alleles from independent screens
in two separate species is compelling evidence for a role of this locus in FSM-resistance in
staphylococci. For several of these strains, GlpT mutations were the only identified genetic
changes arising in FSM-resistant staphyloccci. In addition, the homology between
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staphylococcal GlpT orthologs and Gram-negative phosphonate transporters suggests that the
staphylococcal proteins are functionally similar. The finding that lipophilic prodrug MEPi-
cides, which do not require active transport, are still active against the glpT mutant strains indi-
cates that the molecular basis of phosphonate resistance is through loss of GlpT-mediated
transport (Fig 7). The prodrug MEPicides circumvent GlpT, a phosphonate transporter that
we find to be readily mutated in staphylococci. Future studies to address the potential for resis-
tance to MEPicides will also be important; however, in vitro resistance development alone
should not preclude development of this novel class of antibiotics. It has been well documented
that S. aureus, when treated with single therapeutic agents, frequently develops in vitro resis-
tance to therapeutics that remain important front-line treatments [67–70]. Instead, great care
should be taken when designing treatment regimens for infections by microbes that can rap-
idly adapt to antimicrobial pressure, such as staphylococci.
It is important to note that while data indicate that the glpT mutants are resistant to phos-
phonate parent compound 3, the magnitude of resistance is substantially less than that of FSM.
These data suggest that compound 3 may preferentially use an alternative transporter, thereby
bypassing the dependence on GlpT. Surprisingly, staphylococcal glpT mutants are hypersensi-
tive to MEPicide prodrugs, suggesting that after penetration and cleavage by cellular esterases,
the compounds may accumulate intracellularly in the absence of GlpT (Fig 7). Subsequent
studies should examine the cellular transport of the MEPicide compounds, and further,
explore whether synergy exists between the parent and prodrug varieties of this class of inhibi-
tors. Since serum esterases may act on lipophilic ester prodrugs, understanding the molecular
mechanism of prodrug activation in serum and in bacteria will be key to developing prodrugs
that remain stable during transport to the site of infection.
The MEPicide prodrugs, including compounds 2 and 4, represent promising leads for
ongoing preclinical testing and development of new therapeutics for zoonotic staphylococcal
infections. The prodrugs harness the microbial specificity and thus safety of MEP pathway
inhibition, while avoiding the dependency on active GlpT-mediated transport. In addition, we
find that ester modification has a dramatic effect on anti-staphylococcal potency in vitro, sug-
gesting that phosphonate transport limits the anti-bacterial efficacy of FSM and related com-
pounds. Lipophilic ester modifications have previously been employed to improve
pharmacokinetic properties and bioavailability of anti-staphylococcal agents (e.g., cefditoren
pivoxil)[71]. Since MEPicide ester modification at the site of infection is necessary to facilitate
bacterial cell entry of inhibitors, future studies will aim to understand what chemical features
drive intestinal and serum cleavage of the MEPicide prodrugs.
Materials and methods
DXR inhibitors
FSM (Millipore Sigma) and FR-900098 (Millipore Sigma) were resuspended in sterile water.
Compounds 1–4 were synthesized and resuspended in DMSO as previously described
[41,42,53].
Growth inhibition assays of Staphylococcus species
Overnight cultures were diluted 1:200 in LB media and grown at 37˚C until the mid-logarith-
mic phase (OD600 = 0.5–0.8). Cultures were diluted in a 96-well plate to 1 x 10
5 in 150 μL LB
media and treated with inhibitors at concentrations ranging from 2 nM to 100 μM. Bacteria
were grown at 37˚C for 20 h with cyclic shaking at 700 rpm in a FLUOstar Omega microplate
reader (BMG Labtech). Growth was assessed over 20 h by measuring the OD600 at 20 min
increments. The half-maximal inhibitory concentration (IC50) values were determined during
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logarithmic growth using GraphPad Prism software. All experiments were performed at least
in triplicate and data reported represent the mean ± SEM.
Minimum bactericidal (MBC) assay
Overnight cultures were diluted 1:200 in LB media and grown at 37˚C until reaching mid-log-
arithmic phase of growth. Compounds were added to cultures at their respective IC50 and at
10 x IC50, and the bacteria were incubated at 37˚C for 24 h while shaking. Cultures were seri-
ally diluted in 1 X Dulbecco’s Phosphate Buffered Saline (PBS; Gibco) and plated on LB agar.
Colonies were enumerated after overnight growth at 37˚C. Values reflect the mean and stan-
dard deviations of at least three independent experiments.
Sample preparation for mass spectrometry analysis
Overnight cultures of Staphylococcus spp. were diluted 1:200 in LB media and grown at 37˚C
until reaching mid-logarithmic phase. Cultures were then treated for 2 h with FSM at 10x their
IC50 while shaking at 37˚C. For normalization, the OD600 was determined after 2 h of treat-
ment with the DXR inhibitors. Cells were pelleted by centrifugation for 5 min at 3000 x g at
4˚C. The supernatants were removed and cells were washed twice with 1 x PBS (Gibco). The
supernatants were removed and the pellets stored at -80˚C until analysis. MEP intermediates
were extracted from the samples using glass beads (212–300 u) and 600 μL chilled H2O: chlo-
roform: methanol (3:5:12 v/v) spiked with PIPES (piperazine-N,N0-bis(2-ethanesulfonic acid)
as internal standard. The cells were disrupted with the TissueLyser II instrument (Qiagen)
using a microcentrifuge tube adaptor set pre-chilled for 2 min at 20 Hz. The samples were then
centrifuged at 16,000 x g at 4˚C for 10 min, the supernatants collected, and pellet extraction
repeated once more. The supernatants were pooled and 300 μL chloroform and 450 μL of
chilled water were added to the supernatants. The tubes were vortexed and centrifuged. The
upper layer was transferred to a 2 mL tube PVDF filter (ThermoFisher, F2520-5) and centri-
fuged for 5 min at 4,000 x g at 4˚C. The samples were transferred to new tubes and dried using
a speed-vac. The pellets were re-dissolved in 100 μL of 50% acetonitrile.
LC-MS/MS analysis
For LC separation, Luna-NH2 column (3 μm, 150 x 2 mm, Phenomenex) was used flowing at
0.4 mL/min. The gradient of the mobile phases A (20 mM ammonium acetate, pH 9.8, 5% ace-
tonitrile) and B (100% acetonitrile) was as follows: 60% B for 1 min, to 6% B in 3 min, hold at
6% B for 5 min, then back to 60% B for 0.5 min. The LC system was interfaced with a Sciex
QTRAP 6500+ mass spectrometer equipped with a TurboIonSpray (TIS) electrospray ion
source. Analyst software (version 1.6.3) was used to control sample acquisition and data analy-
sis. The QTRAP 6500+ mass spectrometer was tuned and calibrated according to the manufac-
turer’s recommendations. The metabolites were detected using MRM transitions that were
previously optimized using standards. The instrument was set-up to acquire in negative mode.
For quantification, an external standard curve was prepared using a series of standard samples
containing different concentrations of metabolites and a fixed concentration of the internal
standard. The limit of detection for 1-deoxy-D-xylulose 5-phosphate (DOXP), 4-diphosphocy-
tidyl-2-C-methylerythritol (CDP-ME), and 2-C-methyl-D-erythritol 2,4-cyclopyrophosphate
(MEcPP) was 0.0064 μM for a 10 μL injection volume. Data reflect the mean and SD of at least
three independent experiments. Student’s t-tests were used to test for significance between
untreated (UNT) and drug-treated bacteria (Prism).
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Recombinant expression and purification of DXR
Wild-type dxr from S. schleiferi was amplified from genomic DNA using the forward primer
5’-CTCACCACCACCACCACCAT ATGAAAAATATAGCAATTTTAGGCGC-3’ and the
reverse primer 3’-ATCCTATCTTACT CACCTACACCTCATATGATTTTGTTTTATAAT-5’
The PCR product was cloned into vector BG1861 by ligation-independent cloning to intro-
duce a N-terminal 6xHis tag, and transformed into Stellar chemically competent cells (Clon-
tech Laboratories)[72]. The sequence was confirmed by Sanger sequencing and the plasmid
was transformed into E. coli BL21(DE3) pLysS (Life Technologies). Gene expression was
induced for 2 h with 1 mM isopropyl-β-D-thiogalactoside (IPTG) and cells were harvested by
centrifugation at 4274 x g for 10 min at 4˚C. The cell pellet was lysed by sonication in lysis
buffer containing 25 mM Tris HCl (pH 7.5), 100 mM NaCl, 20 mM imidazole, 10% glycerol, 1
mM MgCl2, 1 mM dithiothreitol (DTT), 1 mg/mL lysozyme, 75 U benzonase and 1 Complete
Mini EDTA-free protease inhibitor tablet (Roche Applied Science). The hexahistidine-tagged
DXR protein was affinity purified from soluble lysate via nickel agarose beads (Gold Biotech-
nology). Bound protein was eluted in 300 mM imidazole, 25 mM Tris HCl (pH 7.5), 1 mM
MgCl2 and 100 mM NaCl. Purified protein was dialyzed in buffer containing 10% glycerol
without imidazole prior to analysis. The enzyme was frozen in liquid nitrogen and stored per-
manently at -80˚C.
DXR enzyme activity and inhibitory constant determination
Oxidation of NADPH to NADP+ as a result of substrate turnover was monitored at 340 nm in
a POLARstar Omega microplate reader (BMG Labtech)[73]. The standard reaction had a final
concentration of 62.5 nM purified DXR protein, 0.5 mM NADPH, 100 mM NaCl, 25 mM Tris
pH 7.5, 10% glycerol, 1 mM MgCl2 and 0.09 mg/mL BSA in 50 μL volume per assay. Reactions
were initiated by the addition of DOXP after 15 min incubation of the reaction mixture with-
out DOXP at 37˚C. Absorption at 340 nm was measured continuously for up to 45 min. For
Km [DOXP] determination, DOXP concentrations between 0 and 2 mM were tested at 0.5
mM NADPH. The linear range of enzyme activity was determined by varying the DXR con-
centration at 1 mM DOXP and 1 mM NADPH. IC50 assays were performed using the standard
reaction conditions with the respective amount of DXR inhibitor added to obtain the given
final concentrations. Data points from at least three independent replicates were analyzed by
nonlinear regression using GraphPad Prism software. Slopes of changing absorbance values
were converted to (μM DOXP)(mg enzyme)-1 s -1 using a NADPH standard curve (data not
shown). For the determination of the inhibitory constant Ki [FSM] of DXR, enzyme activity
over a range of DOXP substrate concentrations between 0 and 2 mM was measured for FSM
between 0 mM to 4 mM. Data points from at least three independent replicates were analyzed
as described above.
Protein crystallography
Crystals of S. schleiferi DXR were grown at 4˚C using the vapor diffusion method in hanging
drops of a 1:1 mixture of protein (10 mg mL-1) and crystallization buffer (2 M ammonium sul-
fate, 100 mM sodium citrate/citric acid, pH 5.5). Crystals of the S. schleiferi DXR•FSM complex
were obtained in 100 mM HEPES/MOPS (pH 7.5), 20 mM D-glucose, 20 mM D-mannose, 20
mM D-galactose, 20 mM L-fucose, 20 mM D-xylose, 20 mM N-acetyl-D-glucosamine, 20%
glycerol, 10% PEG 4000, and 2 mM FSM. Prior to data collection, crystals were stabilized in
cryoprotectant (mother liquor supplemented with 30% glycerol) before flash freezing in liquid
nitrogen for data collection at 100 K. All diffraction images were collected at beamline 19-ID
of the Argonne National Laboratory Advanced Photon Source at Argonne National
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Laboratory. HKL3000 was used to index, integrate, and scale the data sets[74]. For phasing of
the apoenzyme structure, molecular replacement was performed in PHASER using the x-ray
crystal structure of E. coli DXR (PDB: 1T1S) as a search model[31,75]. Two monomers were
found in the asymmetric unit, with each forming a physiological dimer by crystallographic
symmetry. For iterative rounds of model building and refinement, COOT and PHENIX were
used, respectively[76,77]. The resulting model was used to solve the structure of the FSM com-
plex by molecular replacement with PHASER. Two molecules were found in the asymmetric
unit with crystallographic symmetry completing each dimer. Data collection and refinement
statistics are summarized in S2 Table. Atomic coordinates and structure factors of S. schleiferi
DXR (PDB:6MH4) and the S. schleiferi DXR•FSM complex (PDB:6MH5) were deposited in
the RCSB Protein Data Bank.
Generation of FSM-resistant mutants in S. schleiferi and S.
pseudintermedius
Clinical isolates of S. schleiferi (S53022327s) and S. pseudintermedius (H20421242p) were
cloned and adapted to laboratory media via four rounds of sequential colony isolation and
growth on LB agar plates. The isolated FSM-sensitive parental clones were incubated overnight
on LB agar containing FSM (32 μM). Surviving single colonies were re-struck onto LB agar for
clonal isolation. FSM resistance of isolated clones was confirmed by overnight growth on LB
agar containing FSM (32 μM). The FSM-sensitive parental clones were used as a control to
confirm growth and antibiotic-resistance.
Quantification of MEPicide potency
Minimum Inhibitory Concentration (MIC) assays were conducted by microtiter broth dilu-
tion in clear 96-well plates[78]. MEPicides were serially diluted in duplicate at concentrations
ranging from 1.5 mM– 19.5 nM in 75 μL of LB broth. Bacteria cultured without drug were
used as a positive control for growth. The plates were inoculated with 75 μL bacteria diluted to
1 x 105 CFU/mL in LB. Plates were incubated for 18–20 h while shaking at 200 RPM at 37˚C.
The plates were then visually inspected, and the MIC value was defined as the lowest concen-
tration of MEPicide that prevented visual growth.
Whole genome sequencing and variant discovery
Genomic DNA was isolated from overnight cultures of S. pseudintermedius and S. schleiferi
using a standard phenol-chloroform extraction and ethanol precipitation protocol. Sequencing
libraries were prepared and sequenced by the Washington University Genome Technology
Access Center (GTAC). 1 μg of DNA was sonicated to an average size of 175 bp. Fragments
were blunt ended and had an A base added to the 3´ end. Sequence adapters were ligated to
the ends and the sequence tags were added via amplification. Resulting libraries were
sequenced on an Illumina HiSeq 2500 to generate 101 bp paired end reads. DNA quantity and
quality were assessed by GTAC using Agilent Tapestation.
For WGS, sequences from GenBank were retrieved from the following organisms: S. pseu-
dintermedius ED99 (accession number CP002478) and S. schleiferi 1360–13 (CP009740)
assemblies were downloaded from NCBI (ftp://ftp.ncbi.nlm.nih.gov). Paired-end reads were
aligned to each of the available genomes using Novoalign v3.03. (Novocraft Technologies).
Duplicates were removed and variants were called using SAMtools[79]. SNPs were filtered
against parent variants and by mean depth value and quality score (minDP = 5, minQ = 37)
[80]. Genetic variants were annotated using SnpEff v4.3 (S4 Table)[81]. For all samples, at least
90% of the genome was sequenced at 20x coverage. All whole genome sequencing data is
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available in the NCBI BioProject database and Sequence Read Archive. Point mutations found
in the GlpT domain were mapped onto the predicted transmembrane topology of GlpT using
Protter[82].
Sanger Sequencing of S. schleiferi and S. pseudintermedius glpT
Reference sequences for glpT in S. schleiferi (WP_016426432.1) and S. pseudintermedius
(WP_014613322.1) were found with the Basic Local Alignment Search Tool (BLAST, v. 2/2/
22). The regions of interest were amplified from S. pseudintermedius and S. schleiferi using
gene-specific primers (S1 Table). Amplicons were sequenced by the Washington University
Protein and Nucleic Acid Laboratory using BigDye Terminator v3.1 Cycle Sequencing
reagents (Life Technologies). Representative traces for all strains are available through the
NCBI Trace Archive.
Quantification of Intracellular FSM
Overnight cultures of Staphylococcus spp. were diluted in LB media and grown at 37˚C until
reaching mid-logarithmic phase. Cultures were then treated with FSM at 10x the WT IC50
(7.8 μM) while shaking at 37˚C. At the time points indicated, 15 mL of each culture was trans-
ferred to fresh tube and the cells were pelleted by centrifugation for 10 min at 3000 x g at 4˚C.
The supernatants were removed and the pellets resuspended by vortexing in 200 μL acetoni-
trile with 100 ng/mL enalapril. Samples were stored at -80˚C until LC-MS analysis.
The intracellular concentration of FSM was determined by LC-MS (AB Sciex API4000, Fos-
ter City, CA) operated in MRM mode with negative electrospray ionization. The monitored
mass transitions for FSM and enalapril were m/z: 181.909>135.700 and 375.090>114.100,
respectively. Samples were injected onto an Armor C18 column (3 cm x 2.1 mm x 5 um, Ana-
lytical Sales and Services, Flanders, NJ), and eluted with a gradient. Mobile phase A was 0.1%
formic acid in water and mobile phase B was 0.1% formic acid in acetonitrile. Samples of cells
were thoroughly mixed in acetonitrile containing enalapril as an internal standard to precipi-
tate proteins and then centrifuged at 3200 rpm for 5 min. The acetonitrile was transferred to a
96-well plate and allowed to evaporate to dryness under nitrogen. The samples were reconsti-
tuted in 150 μL of mobile phase A before analysis. The gradient program for the LC held
mobile phase B at 2% for 0.1 min before ramping to 100% mobile phase B in 1 min at a flow
rate of 0.4 mL/min. Data analysis was performed using Analyst software (AB Sciex, Foster
City, CA). Standards were prepared by addition of FSM to blank cellular preparations over a
concentration range of 1 ng/mL to 500 ng/mL.
Supporting information
S1 Fig. DXR inhibitors are bacteriostatic. Growth in CFU/mL of S. schleiferi and S. pseudin-
termedius after 24 h treatment is plotted against the respective treatment. Cultures were treated
at 1 x IC50 concentration and/or 10x IC50 concentration of the inhibitors. Shown are the mean
values + SD from at least three independent experiments.
(EPS)
S2 Fig. SDS-PAGE of purified S. schleiferi DXR. Molecular mass standard (M) and approxi-
mately 1 μg of purified recombinant S. schleiferi DXR.
(EPS)
S3 Fig. Membrane topology of GlpT. (A) Wild-type amino acid sequences and predicted
transmembrane topology of S. schleiferi GlpT. Residues Gly-99, Trp-148, Trp-161, Ala-267,
Gly-298, Ala-309, and Gln-379 are indicated in the sequence. Red indicates a stop mutation at
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the site, while blue indicates a missense mutation. (B) Wild-type amino acid sequences and
predicted transmembrane topology of S. pseudintermedius GlpT. Residues Asp-88, Gly-99,
Gly-135, Trp-301, Gly-400, and Gly-404 are indicated in the sequence. Red indicates a stop
mutation at the site, while blue indicates a missense mutation. Schematic diagrams were pre-




S2 Table. Summary of crystallographic data collection and refinement statistics.
(XLSX)
S3 Table. FSM MICs, glpT alleles, GlpT protein changes, and Polyphen-2 scores for FSMR
strains.
(DOCX)
S4 Table. SNP calls from FSMR S. schleiferi and S. pseudintermedius strains. Genomes were
aligned to reference genomes S. schleiferi 1360–13 and S. pseudintermedius ED99, respectively.
Each line represents a SNP call. Changes shown are those not present in the parental strain.
Changes determined to be false by Sanger sequencing have been removed. GlpT is highlighted
in green. �Location of the change inside the gene, †the base at that location, ‡the new base pres-
ent at that location, §the corresponding protein change associated with the new base, ¶the gene
name according to the previous annotation, #the predicted function.
(XLS)
S5 Table. Inhibitory effect of MEPicides against a panel of Gram-negative bacteria. IC50
values are reported in μM. Data represent the mean ± SD from at least three independent
experiments.
(XLSX)
S1 File. Supplemental methods.
(DOCX)
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be misdiagnosed as Staphylococcus aureus in humans with dog bite wounds. Eur J Clin Microbiol Infect
Dis. 2015 Apr 23; 34(4):839–44. https://doi.org/10.1007/s10096-014-2300-y PMID: 25532507
4. Lainhart W, Yarbrough ML, Burnham CA. The brief case: Staphylococcus intermedius group-look what
the dog dragged in. J Clin Microbiol. 2018 Feb; 56(2).
5. Rojas-Marte G, Victor J, Shenoy A, Yakubov S, Chapnick E, Lin YS. Pacemaker-associated infective
endocarditis caused by Staphylococcus schleiferi. Infect Dis Clin Pract. 2014; 22(5):302–4.
6. Pottumarthy S, Schapiro JM, Prentice JL, Houze YB, Swanzy SR, Fang FC, et al. Clinical isolates of
Staphylococcus intermedius masquerading as methicillin-resistant Staphylococcus aureus. J Clin
Microbiol. 2004 Dec 1; 42(12):5881–4. https://doi.org/10.1128/JCM.42.12.5881-5884.2004 PMID:
15583331
7. Yarbrough ML, Lainhart W, Burnham CA. Epidemiology, clinical characteristics, and antimicrobial sus-
ceptibility profiles of human clinical isolates of Staphylococcus intermedius group. J Clin Microbiol. 2018
Mar 1; 56(3):e01788–17. https://doi.org/10.1128/JCM.01788-17 PMID: 29305548
8. Ross Fitzgerald J. The Staphylococcus intermedius group of bacterial pathogens: species re-classifica-
tion, pathogenesis and the emergence of meticillin resistance. Vet Dermatol. 2009 Oct; 20(5–6):490–5.
https://doi.org/10.1111/j.1365-3164.2009.00828.x PMID: 20178486
9. Humphries RM, Wu MT, Westblade LF, Robertson AE, Burnham C-AD, Wallace MA, et al. In vitro anti-
microbial susceptibility of Staphylococcus pseudintermedius isolates of human and animal origin. J Clin
Microbiol. 2016; 54(5):1391–4. https://doi.org/10.1128/JCM.00270-16 PMID: 26962087
10. Beever L, Bond R, Graham PA, Jackson B, Lloyd DH, Loeffler A. Increasing antimicrobial resistance in
clinical isolates of Staphylococcus intermedius group bacteria and emergence of MRSP in the UK. Vet
Rec. 2015 Feb 14; 176(7):172. https://doi.org/10.1136/vr.102651 PMID: 25376505
11. Lange BM, Rujan T, Martin W, Croteau R. Isoprenoid biosynthesis: The evolution of two ancient and
distinct pathways across genomes. Proc Natl Acad Sci. 2000; 97(24):13172–7. https://doi.org/10.1073/
pnas.240454797 PMID: 11078528
12. Wilding EI, Kim DY, Bryant AP, Gwynn MN, Lunsford RD, McDevitt D, et al. Essentiality, expression,
and characterization of the class II 3-hydroxy-3-methylglutaryl coenzyme A reductase of Staphylococ-
cus aureus. J Bacteriol. 2000 Sep; 182(18):5147–52. https://doi.org/10.1128/jb.182.18.5147-5152.
2000 PMID: 10960099
13. Matsumoto Y, Yasukawa J, Ishii M, Hayashi Y, Miyazaki S, Sekimizu K. A critical role of mevalonate for
peptidoglycan synthesis in Staphylococcus aureus. Sci Rep. 2016 Mar 10; 6:22894. https://doi.org/10.
1038/srep22894 PMID: 26961421
14. Liu C-I, Liu GY, Song Y, Yin F, Hensler ME, Jeng W-Y, et al. A cholesterol biosynthesis inhibitor blocks
Staphylococcus aureus virulence. Science. 2008 Mar 7; 319(5868):1391–4. https://doi.org/10.1126/
science.1153018 PMID: 18276850
PLOS PATHOGENS MEPicides for zoonotic staph
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1007806 June 4, 2020 18 / 22
15. Misic AM, Cain CL, Morris DO, Rankin SC, Beiting DP. Divergent isoprenoid biosynthesis pathways in
Staphylococcus species constitute a drug target for treating infections in companion animals. mSphere.
2014; 1(5):1–11.
16. Nair SC, Brooks CF, Goodman CD, Sturm A, Strurm A, McFadden GI, et al. Apicoplast isoprenoid pre-
cursor synthesis and the molecular basis of fosmidomycin resistance in Toxoplasma gondii. J Exp Med.
2011 Jul 4; 208(7):1547–59. https://doi.org/10.1084/jem.20110039 PMID: 21690250
17. Odom AR, Van Voorhis WC. Functional genetic analysis of the Plasmodium falciparum deoxyxylulose
5-phosphate reductoisomerase gene. Mol Biochem Parasitol. 2010 Apr; 170(2):108–11. https://doi.org/
10.1016/j.molbiopara.2009.12.001 PMID: 20018214
18. Brown AC, Parish T. Dxr is essential in Mycobacterium tuberculosis and fosmidomycin resistance is
due to a lack of uptake. BMC Microbiol. 2008 May 20; 8:78. https://doi.org/10.1186/1471-2180-8-78
PMID: 18489786
19. McAteer S, Coulson A, McLennan N, Masters M. The lytB gene of Escherichia coli is essential and
specifies a product needed for isoprenoid biosynthesis. J Bacteriol. 2001 Dec; 183(24):7403–7. https://
doi.org/10.1128/JB.183.24.7403-7407.2001 PMID: 11717301
20. Wagner WP, Helmig D, Fall R. Isoprene biosynthesis in Bacillus subtilis via the methylerythritol phos-
phate pathway. J Nat Prod. 2000 Jan 63(1):37–40. https://doi.org/10.1021/np990286p PMID:
10650075
21. McKenney ES, Sargent M, Khan H, Uh E, Jackson ER, San Jose G, et al. Lipophilic prodrugs of
FR900098 are antimicrobial against Francisella novicida in vivo and in vitro and show GlpT independent
efficacy. PLoS One. 2012; 7(10):e38167. https://doi.org/10.1371/journal.pone.0038167 PMID:
23077474
22. Koppisch AT, Fox DT, Blagg BSJ, Poulter CD. E. coli MEP synthase: Steady-state kinetic analysis and
substrate binding. Biochemistry. 2002; 41(1):236–43. https://doi.org/10.1021/bi0118207 PMID:
11772021
23. Kuemmerle HP, Murakawa T, Sakamoto H, Sato N, Konishi T, De Santis F. Fosmidomycin, a new phos-
phonic acid antibiotic. Part II: 1. Human pharmacokinetics. 2. Preliminary early phase IIa clinical studies.
Int J Clin Pharmacol Ther Toxicol. 1985 Oct; 23(10):521–8. PMID: 4066076
24. Borrmann S, Lundgren I, Oyakhirome S, Impouma B, Matsiegui P-B, Adegnika AA, et al. Fosmidomycin
plus clindamycin for treatment of pediatric patients aged 1 to 14 years with Plasmodium falciparum
malaria. Antimicrob Agents Chemother. 2006 Aug 1; 50(8):2713–8. https://doi.org/10.1128/AAC.
00392-06 PMID: 16870763
25. Tsuchiya T, Ishibashi K, Terakawa M, Nishiyama M, Itoh N, Noguchi H. Pharmacokinetics and metabo-
lism of fosmidomycin, a new phosphonic acid, in rats and dogs. Eur J Drug Metab Pharmacokinet.1982;
7(1):59–64. https://doi.org/10.1007/BF03189544 PMID: 7067725
26. Dhiman RK, Schaeffer ML, Bailey AM, Testa CA, Scherman H, Crick DC. 1-deoxy-D-xylulose 5-phos-
phate reductoisomerase (IspC) from Mycobacterium tuberculosis: towards understanding mycobacte-
rial resistance to fosmidomycin. J Bacteriol. 2005 Dec; 187(24):8395–402. https://doi.org/10.1128/JB.
187.24.8395-8402.2005 PMID: 16321944
27. Mackie RS, McKenney ES, van Hoek ML. Resistance of Francisella novicida to fosmidomycin associ-
ated with mutations in the glycerol-3-phosphate transporter. Front Microbiol. 2012; 3:226. https://doi.
org/10.3389/fmicb.2012.00226 PMID: 22905031
28. Sakamoto Y, Furukawa S, Ogihara H, Yamasaki M. Fosmidomycin resistance in adenylate cyclase defi-
cient (cya) mutants of Escherichia coli. Biosci Biotechnol Biochem. 2003 Jan 22; 67(9):2030–3. https://
doi.org/10.1271/bbb.67.2030 PMID: 14519998
29. Argyrou A, Blanchard JS. Kinetic and chemical mechanism of Mycobacterium tuberculosis 1-deoxy-D-
xylulose-5-phosphate isomeroreductase. Biochemistry. 2004; 43(14):4375–84. https://doi.org/10.1021/
bi049974k PMID: 15065882
30. Kuzuyama T, Takahashi S, Takagi M, Seto H. Characterization of 1-deoxy-D-xylulose 5-phosphate
reductoisomerase, an enzyme involved in isopentenyl diphosphate biosynthesis, and identification of its
catalytic amino acid residues. J Biol Chem. 2000; 275(26):19928–32. https://doi.org/10.1074/jbc.
M001820200 PMID: 10787409
31. Yajima Shunsuke, Hara Kodai, Sanders John M., Yin Fenglin, Ohsawa Kanju, Wiesner Jochen, et al.
Crystallographic structures of two bisphosphonate:1-deoxyxylulose-5-phosphate reductoisomerase
complexes. 2004; 126(35):10824–10825. https://doi.org/10.1021/ja040126m PMID: 15339150
32. Yajima S, Nonaka T, Kuzuyama T, Seto H, Ohsawa K. Crystal structure of 1-deoxy-D-xylulose 5-phos-
phate reductoisomerase complexed with cofactors: implications of a flexible loop movement upon sub-
strate binding. J Biochem. 2002; 131(3):313–7. https://doi.org/10.1093/oxfordjournals.jbchem.a003105
PMID: 11872159
PLOS PATHOGENS MEPicides for zoonotic staph
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1007806 June 4, 2020 19 / 22
33. Yajima S, Hara K, Iino D, Sasaki Y, Kuzuyama T, Ohsawa K, et al. Structure of 1-deoxy-D-xylulose 5-
phosphate reductoisomerase in a quaternary complex with a magnesium ion, NADPH and the antima-
larial drug fosmidomycin. Acta Crystallogr Sect F Struct Biol Cryst Commun. 2007 Jun 1; 63(Pt 6):466–
70. https://doi.org/10.1107/S1744309107024475 PMID: 17554164
34. Behrendt CT, Kunfermann A, Illarionova V, Matheeussen A, Pein MK, Gräwert T, et al. Reverse fosmi-
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